Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.

Hajime KamiyaShuhei KomatsuYusuke TakashimaRyo IshidaHiroshi ArakawaKeiji NishibeppuJun KiuchiTaisuke ImamuraTakuma OhashiHiroki ShimizuTomohiro AritaHirotaka KonishiAtsushi ShiozakiTakeshi KubotaHitoshi FujiwaraShigeki YagyuTomoko IeharaEigo Otsuji

Published in: British journal of cancer (2023)

Low blood levels of miR-5193 are associated with GC progression and poor outcomes and could be a target of nucleic acid immunotherapy in GC patients.

Keyphrases

nucleic acid
cell proliferation
long non coding rna
end stage renal disease
long noncoding rna
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
metabolic syndrome
patient reported outcomes
mass spectrometry
insulin resistance
liquid chromatography
glycemic control
solid phase extraction